Insider · CIK 0001347582
Anna Protopapas
director
Files at MRSN (Mersana Therapeutics, Inc.), NUVL (Nuvalent, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stock | +2,647 | $0.00 | $0 | 5,146 | Jun 20, 2025 |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +4,147 | $0.00 | $0 | 4,147 | Jun 20, 2025 |
| Jun 12, 2025 | MRSN Mersana Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +61,500 | $0.00 | $0 | 61,500 | Jun 13, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.